Tumor location and type
Upper, middle, lower esophagus or gastroesophageal junction location and squamous/adenocarcinoma histology are clarified.
Oncology evaluation directory
Gastrointestinal oncology
Esophageal Cancer Evaluation
A clinical coordination page for esophageal cancer, focused on tumor location, histology, swallowing safety, nutrition, staging, prior chemoradiation or surgery and biomarker context where relevant.
Medical disclaimer: This page is informational and coordination-focused. It does not diagnose, prescribe, promise treatment suitability or replace urgent local medical care.
Clinical file logic
What the specialist needs to understand before any treatment discussion.
Esophageal cancer review is highly dependent on tumor location, ability to swallow, nutritional status, airway or fistula risk and whether the patient has already received chemoradiation, surgery or systemic therapy.
The file must show more than the cancer name. It should show what the patient can eat, whether a stent or feeding tube is present, how recently staging was done and what treatment has already been completed.
Swallowing and nutrition
Dysphagia grade, weight loss, feeding tube, stent, aspiration and hydration are documented.
Staging workup
Endoscopy, EUS if performed, CT, PET-CT and metastatic evaluation are organized.
Biomarker context
HER2, PD-L1, MSI/MMR or other markers are reviewed when available for advanced disease contexts.
Prior therapy
Chemoradiation, surgery, systemic therapy and dates of recurrence/progression are summarized.
Clinical priority
The specialist question may be second opinion, post-progression options, symptom control or travel feasibility.
Evaluation matrix
How the case is reviewed without reducing it to a diagnosis name.
Each item below affects how the file is interpreted, what the physician can answer and whether additional documents are needed before a responsible response.
Dysphagia risk
Inability to swallow liquids can be urgent and may need local intervention before coordination.
Curative vs metastatic context
Localized, post-surgical, recurrent and metastatic settings require different review logic.
Prior radiation field
Prior chest radiation affects future local treatment discussions and safety.
Nutritional reserve
Albumin, weight loss and functional status can change timing and suitability.
Documents to prepare
A complete medical file prevents delay and unrealistic expectations.
Most delays happen when the diagnosis is described verbally but the file lacks dates, reports, imaging, pathology or the current specialist recommendation. The documents below are requested before the file is considered ready for review.
Cuba context
How Cuba-related options are framed responsibly.
The page does not present a hospital visit or travel plan as automatically suitable. Any Cuba-related discussion remains conditional on physician review of the current file.
No travel before stabilization
Severe swallowing failure, dehydration or infection should be managed locally first.
Specialist question is defined
The file should ask whether a review is useful, not request a guaranteed treatment.
Coordination includes nutrition
Logistics planning includes food tolerance, caregiver needs and treatment fatigue.
Options discussed in Cuba
Oesophageal cancer: nutrition, staging and Cuba-related options
In this diagnosis, safe nutrition has to be solved before any treatment discussion.
In oesophageal cancer the Cuba-related option most often named is nimotuzumab (CIMAher), an EGFR-directed antibody studied in addition to chemoradiotherapy. It is licensed in Cuba for this setting and is given alongside chemoradiotherapy. The option is considered after standard approaches have been assessed, with oncology agreement.
What shapes the plan here is tumour location (upper, middle or lower third), histological type (squamous cell carcinoma or adenocarcinoma), stage, and HER2 and PD-L1 status. In adenocarcinoma, HER2 positivity can change treatment selection, so the pathology report must be complete.
Difficulty swallowing and weight loss affect both clinical decisions and travel safety. If solids cannot be swallowed, if intake depends on liquids, or if there has been marked recent weight loss, securing the feeding route comes first. Long journeys planned before that can worsen the patient's condition.
Nutritional status
Weight change over the last six months, tolerance of solids and liquids, and any feeding tube should be documented.
Complete pathology
Histological type, grade, HER2 and PD-L1 status directly determine treatment selection.
Staging imaging
Endoscopy report, endoscopic ultrasound where performed, CT and PET-CT establish the extent of disease.
When local care comes first
Do not wait for international review if urgent symptoms are present.
International coordination should never delay emergency care. If any of the following are present, the patient should be assessed locally first.
- Unable to swallow liquids, repeated aspiration, dehydration or severe vomiting.
- Bleeding, chest pain, fever or suspected fistula/perforation.
- Rapid weight loss with severe weakness or confusion.
Coordination pathway
From records to written next steps.
- File intakeReports, imaging, summaries and current symptoms are uploaded through the application flow.
- Quality checkThe coordination team checks readability, dates, translation needs and missing items.
- Specialist routingThe case is prepared around a clear medical question and routed to the relevant review pathway.
- Written responseThe patient receives an organized next-step explanation before travel, payment or treatment logistics are considered.
Questions
Before starting the application.
Does this page mean I am suitable for a Cuba-based treatment?
No. It explains how the file is organized for review. Suitability, route, timing and safety can only be determined by physicians after reviewing the complete current record.
Can I send only a short summary?
A summary helps, but it is not enough for most oncology reviews. Pathology, imaging, treatment history, lab results and the latest oncology note are usually needed.
Will the coordinator choose my treatment?
No. Cuba Health Assist coordinates records, communication, translation support and logistics. Medical decisions remain with licensed physicians and the patient’s treating team.
What happens if my file is incomplete?
The team will request missing reports before presenting the case as ready. This protects the patient from receiving a weak or unrealistic response.
Can urgent symptoms be handled through this page?
No. Severe or rapidly worsening symptoms require local emergency or oncology care first. International coordination is not an emergency service.
Related evaluation pages
Other oncology files reviewed in the same clinical directory.
Official product information
CIMAher (nimotuzumab) as licensed in Cuba
The data below are taken from the product summary approved by CECMED, the Cuban medicines regulator. They describe the product as licensed in Cuba and are not a treatment recommendation.
- Registration
- Sanitary registration 1745, registered 19 February 2002
- Manufacturer
- Center of Molecular Immunology (CIM), Havana, Cuba
- Approved indications
- Advanced squamous cell carcinoma of the head and neck in combination with radiotherapy or chemoradiotherapy, including nasopharyngeal tumours in stages III/IV with radiotherapy; adult high-grade glioma (glioblastoma multiforme and anaplastic astrocytoma) with radiotherapy; newly diagnosed paediatric high-grade glioma with radiotherapy or chemoradiotherapy; recurrent or refractory paediatric glioma as monotherapy; locally advanced, inoperable oesophageal cancer with chemoradiotherapy.
- Route and schedule
- Intravenous infusion. Adults: 200 mg once weekly for six weeks concurrently with radiotherapy or chemoradiotherapy (induction), then 200 mg every two weeks (maintenance) until clinical progression or intolerance. Paediatric recurrent or refractory glioma as monotherapy: 150 mg/m² weekly for six weeks, then every two weeks.
- Monitoring
- Must be given under the supervision of a physician experienced with intravenous medicines, with close observation during the infusion and for at least one hour afterwards. No premedication is required.
- Contraindications
- History of hypersensitivity to this product, to other products derived from mammalian cells, or to any component of the formulation.
- Reported effects
- Adverse reactions reported in pre- and post-authorisation studies include tremor, chills, nausea, headache, vomiting, anaemia and lowered or raised blood pressure.
Approval in Cuba does not mean approval in your country, and it does not mean the product is suitable for you. Eligibility is decided by the physician who reviews your complete file.
Start with the file
Submit documents before making a travel or treatment decision.
A coordinator will organize the medical information and guide the next step according to specialist review. The process is designed to be transparent, clinically cautious and written.